Replimune REPL
NASDAQ REPL
$13.07 -0.38 (-2.83%)
At close: Oct 2, 2026 · 4:00 PM EDT

Replimune (REPL) Return on Equity [ROE] (2018 - 2026)

Updated

Replimune (REPL) reported Return on Equity [ROE] of -217.10% for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 142.49 percentage points from -74.61% a year earlier and down 50.73 percentage points from the prior quarter.

Analysis

Replimune (REPL) Return on Equity [ROE] (2018 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Replimune posted Return on Equity [ROE] of -108.07%, down 45.61 percentage points from FY2025.

  • Return on Equity [ROE] has declined for five consecutive fiscal years, with a five-year change of -84.67 percentage points (FY2021 to FY2026).
  • By fiscal year, Return on Equity [ROE] came in at -62.46% in FY2025 (-16.13 pp), -46.33% in FY2024 (-10.32 pp), -36.00% in FY2023 (-10.06 pp) and -25.94% in FY2022 (-2.54 pp).
  • The fiscal Q1 2027 figure ranks as the lowest quarterly Return on Equity [ROE] in data going back to fiscal Q2 2019.
  • Year over year, Return on Equity [ROE] has now declined in each of the last 19 quarters, with an average year-over-year change of -52.79 percentage points over the last eight quarters.
  • The high point for year-over-year Return on Equity [ROE] in five years was fiscal Q2 2022 (a gain of 4.75 percentage points); the low point was fiscal Q1 2027 (a drop of 142.49 percentage points).
  • Per Business Quant data, the three fiscal quarters before Q1 2027 came in at -166.37% (Q4 2026), -132.66% (Q3 2026) and -103.25% (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 25.32%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 84.40%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 21.39%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 83.75%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -18.38%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 4.97%
10 Replimune 1.13 Bn 1.13 Bn - -217.10%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -217.10%
Mar 31, 2026 -166.37%
Dec 31, 2025 -132.66%
Sep 30, 2025 -103.25%
Jun 30, 2025 -74.61%
Mar 31, 2025 -55.07%
Dec 31, 2024 -52.84%
Sep 30, 2024 -52.73%
Jun 30, 2024 -54.94%
Mar 31, 2024 -54.22%
Dec 31, 2023 -47.37%
Sep 30, 2023 -40.55%
Jun 30, 2023 -33.97%
Mar 31, 2023 -30.30%
Dec 31, 2022 -32.04%
Sep 30, 2022 -36.97%
Jun 30, 2022 -32.35%
Mar 31, 2022 -27.79%
Dec 31, 2021 -24.17%
Sep 30, 2021 -21.13%
API Access

Replimune Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=REPL&period=max&api_key=YOUR_API_KEY